Barclays Maintains Overweight on SpringWorks Therapeutics, Raises Price Target to $63
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson maintains an Overweight rating on SpringWorks Therapeutics (SWTX) and raises the price target from $47 to $63.
February 29, 2024 | 1:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays has raised the price target for SpringWorks Therapeutics from $47 to $63 while maintaining an Overweight rating.
The increase in price target by a reputable analyst like Peter Lawson from Barclays indicates a strong bullish outlook on SWTX, likely leading to positive investor sentiment and potential short-term price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100